Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07422298 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

A Phase 1 study of Healthy Volunteers, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT07422298 is a Phase 1 study of Healthy Volunteers that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 32 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07422298, a Phase 1 study of Healthy Volunteers, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the effect of BMS-986278 on the cardiac repolarization in healthy participants.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Moxifloxacin
  • DRUG BMS-986278

Study Locations (1)

Texas

  • Worldwide Clinical Trials - San Antonio

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2026-02-19
Est. Completion 2026-06-15
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT07422298

The ClinicalTrials.gov registry entry for NCT07422298 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (93% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT07422298 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT07422298 about?

NCT07422298 is a clinical study titled "A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants". The purpose of this study is to evaluate the effect of BMS-986278 on the cardiac repolarization in healthy participants.

What is the current status of trial NCT07422298?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-02-19. Estimated completion is 2026-06-15.

What conditions does trial NCT07422298 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT07422298?

The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), BMS-986278 (DRUG).

Who is sponsoring clinical trial NCT07422298?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07422298 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.